Showing results (141-150 of 757) with videos related to
Sort By:
Pageof 76
Drug Safety|October 1, 1996
The clinical implications of inhibition of the inducible form of cyclo-oxygenaseC Richardson, P EmeryBritish Journal of Rheumatology|February 1, 1986
A double-blind study of the simple analgesic nefopam in rheumatoid arthritisP Emery, T GibsonAnnals of the Rheumatic Diseases|November 1, 2011
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of responseP Emery, T DörnerBritish Journal of Hospital Medicine|March 1, 1991
The immune response. 2. Systemic mediators of inflammationP Emery, M SalmonExpert Opinion on Pharmacotherapy|May 5, 2001
Leflunomide: a novel DMARD for the treatment of rheumatoid arthritisA Alldred, P EmeryClinical and Experimental Rheumatology|February 19, 2004
Role of biologics in early arthritisP Emery, Y SetoThe Journal of the Acoustical Society of America|August 18, 2001
Category restructuring during second-language speech acquisitionI R MacKay, J E Flege, T Piske, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1983
Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancerI R Mackay, M D Goodyear, C Riglar, et al.The Medical Journal of Australia|March 2, 1987
Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigenI H Frazer, B Jones, M Dimitrakakis, et al.Pageof 76